MPLT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
MapLight Therapeutics Inc (MPLT) does not present a strong buy opportunity for a beginner, long-term investor with $50,000-$100,000 available for investment. While there is some positive sentiment from analysts and a potential upside risk/reward, the lack of significant financial growth, absence of strong trading signals, and neutral insider and hedge fund activity suggest it is better to hold off on purchasing this stock at the moment.
The MACD is positive and expanding, indicating a bullish trend. RSI is neutral at 61.564, and moving averages are converging, suggesting no strong directional trend. The stock is trading near its resistance level (R1: 18.535) in pre-market, which could limit immediate upside potential.
Stifel analyst sees upside risk/reward for MPLT due to its muscarinic drug's potential wider therapeutic index in elderly subjects. Current valuation is considered low, pricing in minimal ADP credit.
Financial performance shows no growth in revenue, net income, or EPS. Insider and hedge fund activity are neutral, and there are no significant trading trends. No recent news or congress trading data to act as a catalyst.
In Q2 2024, the company reported no revenue growth (0% YoY), a net income of -$18.4 million, and an EPS of -1.26, all showing no improvement YoY. Gross margin remains at 0%.
Stifel maintains a Buy rating with a $28 price target, citing upside potential. However, lingering questions about the ADEPT-2 study and trial irregularities create uncertainty.
